MedTrace Logo

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-06-29

No results posted yet for this study

Summary

The aim of this study is to understand how TAK-994 is processed by the body.

This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.

Conditions

  • Healthy Volunteers

Interventions

DRUG

TAK-994 Oral Tablet

TAK-994 tablet.

DRUG

[14C]TAK-994 Intravenous Infusion

\[14C\]TAK-994 intravenous infusion.

DRUG

[14C]TAK-994 Oral Suspension

\[14C\]TAK-994 oral suspension.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-14
Primary Completion
2021-06-20
Completion
2021-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833049 on ClinicalTrials.gov